322 related articles for article (PubMed ID: 23083810)
1. Sense from nonsense: therapies for premature stop codon diseases.
Bidou L; Allamand V; Rousset JP; Namy O
Trends Mol Med; 2012 Nov; 18(11):679-88. PubMed ID: 23083810
[TBL] [Abstract][Full Text] [Related]
2. [Allele-specific therapy: suppression of nonsense mutations by readthrough inducers].
Floquet C; Rousset JP; Bidou L
Med Sci (Paris); 2012 Feb; 28(2):193-9. PubMed ID: 22377308
[TBL] [Abstract][Full Text] [Related]
3. Cancer syndromes and therapy by stop-codon readthrough.
Bordeira-Carriço R; Pêgo AP; Santos M; Oliveira C
Trends Mol Med; 2012 Nov; 18(11):667-78. PubMed ID: 23044248
[TBL] [Abstract][Full Text] [Related]
4. Therapeutics based on stop codon readthrough.
Keeling KM; Xue X; Gunn G; Bedwell DM
Annu Rev Genomics Hum Genet; 2014; 15():371-94. PubMed ID: 24773318
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical therapies to recode nonsense mutations in inherited diseases.
Lee HL; Dougherty JP
Pharmacol Ther; 2012 Nov; 136(2):227-66. PubMed ID: 22820013
[TBL] [Abstract][Full Text] [Related]
6. Aminoglycoside-induced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy.
Zingman LV; Park S; Olson TM; Alekseev AE; Terzic A
Clin Pharmacol Ther; 2007 Jan; 81(1):99-103. PubMed ID: 17186006
[TBL] [Abstract][Full Text] [Related]
7. Introducing sense into nonsense in treatments of human genetic diseases.
Linde L; Kerem B
Trends Genet; 2008 Nov; 24(11):552-63. PubMed ID: 18937996
[TBL] [Abstract][Full Text] [Related]
8. Emerging Personalized Opportunities for Enhancing Translational Readthrough in Rare Genetic Diseases and Beyond.
Wagner RN; Wießner M; Friedrich A; Zandanell J; Breitenbach-Koller H; Bauer JW
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047074
[TBL] [Abstract][Full Text] [Related]
9. Nonsense suppression therapies in human genetic diseases.
Martins-Dias P; Romão L
Cell Mol Life Sci; 2021 May; 78(10):4677-4701. PubMed ID: 33751142
[TBL] [Abstract][Full Text] [Related]
10. Nonsense suppression therapies in ocular genetic diseases.
Wang X; Gregory-Evans CY
Cell Mol Life Sci; 2015 May; 72(10):1931-8. PubMed ID: 25651836
[TBL] [Abstract][Full Text] [Related]
11. Effect of small molecule eRF3 degraders on premature termination codon readthrough.
Baradaran-Heravi A; Balgi AD; Hosseini-Farahabadi S; Choi K; Has C; Roberge M
Nucleic Acids Res; 2021 Apr; 49(7):3692-3708. PubMed ID: 33764477
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development.
Rowe SM; Clancy JP
BioDrugs; 2009; 23(3):165-74. PubMed ID: 19627168
[TBL] [Abstract][Full Text] [Related]
13. Suppression of premature termination codons as a therapeutic approach.
Keeling KM; Wang D; Conard SE; Bedwell DM
Crit Rev Biochem Mol Biol; 2012 Sep; 47(5):444-63. PubMed ID: 22672057
[TBL] [Abstract][Full Text] [Related]
14. Translational readthrough induction of pathogenic nonsense mutations.
Kellermayer R
Eur J Med Genet; 2006; 49(6):445-50. PubMed ID: 16740421
[TBL] [Abstract][Full Text] [Related]
15. Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells.
Bidou L; Bugaud O; Belakhov V; Baasov T; Namy O
RNA Biol; 2017 Mar; 14(3):378-388. PubMed ID: 28145797
[TBL] [Abstract][Full Text] [Related]
16. Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases.
Keeling KM; Bedwell DM
Wiley Interdiscip Rev RNA; 2011; 2(6):837-52. PubMed ID: 21976286
[TBL] [Abstract][Full Text] [Related]
17. Dbp5/DDX19 between Translational Readthrough and Nonsense Mediated Decay.
Beißel C; Grosse S; Krebber H
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32041247
[TBL] [Abstract][Full Text] [Related]
18. A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion.
Sharma J; Du M; Wong E; Mutyam V; Li Y; Chen J; Wangen J; Thrasher K; Fu L; Peng N; Tang L; Liu K; Mathew B; Bostwick RJ; Augelli-Szafran CE; Bihler H; Liang F; Mahiou J; Saltz J; Rab A; Hong J; Sorscher EJ; Mendenhall EM; Coppola CJ; Keeling KM; Green R; Mense M; Suto MJ; Rowe SM; Bedwell DM
Nat Commun; 2021 Jul; 12(1):4358. PubMed ID: 34272367
[TBL] [Abstract][Full Text] [Related]
19. Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development.
Li S; Li J; Shi W; Nie Z; Zhang S; Ma F; Hu J; Chen J; Li P; Xie X
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371567
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of the initiation of mRNA decay: role of eRF3 family G proteins.
Hoshino S
Wiley Interdiscip Rev RNA; 2012; 3(6):743-57. PubMed ID: 22965901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
